Truffle Capital, an investor in Vexim, is a European private equity firm originally set up for investments in spin-offs from companies active in the IT, Energy, and Life Sciences sectors.
-
Vexim, set up in 2006 as a spin-off from Teknimed, a French leader in orthopedic cements, is developing innovative technologies for the surgical treatment of vertebral compression fractures (VCFs). The company has produced a medical device, a vertebral implant, which should counter limitations of available surgical options, and effectively restore vertebral height. The market for VCF is estimated at $1 billion, with over 200,000 cases per annum and growing at 20% a year.
-
Following a €2.4 million investment by Truffle Capital in 2006, Vexim is actively pursuing clinical development and a CE mark
-
Truffle Capital board members: Philippe Pouletty, M.D.